MCAZ: Nifedipine Drug Recall Zimbabwe Issued for Two Batches

• On September 12, 2026, Zimbabwe's Ministry of Health and Child Care confirmed a drug recall initiated by the Medicines Control Authority of Zimbabwe (MCAZ).
• The recall targets specific batches (112033, 117367) of Nifedipine 10mg tablets, manufactured by Cyprus-based Remedica Ltd, due to out-of-specification results from stability testing.
• Nifedipine is widely used for high blood pressure and heart conditions, while Levodopa/Carbidopa tablets, also from Remedica, were flagged for quality issues and are used for Parkinson's disease.
• MCAZ classified this as a Class Two recall, requiring withdrawal from pharmacies, health facilities, and patients.
• This action emphasizes the critical role of post-market surveillance and robust recall protocols for pharmaceutical compliance in Zimbabwe.

For pharmaceutical companies, distributors, and healthcare providers operating in Zimbabwe, this event serves as a stark reminder of the paramount importance of pharmaceutical compliance Zimbabwe.

The Ministry of Health and Child Care in Zimbabwe officially confirmed on September 12, 2026, a significant drug recall initiated by the Medicines Control Authority of Zimbabwe (MCAZ). This action, part of the Authority's routine post-market surveillance activities, targets specific batches of Nifedipine 10mg tablets, a medication widely prescribed across Zimbabwe for managing high blood pressure and various heart-related conditions.

The recall specifically impacts two batches of Nifedipine 10mg tablets, identified as 112033 and 117367. These batches were manufactured by Remedica Ltd, a pharmaceutical company based in Cyprus. The Ministry's statement verified the authenticity of the MCAZ notice that had been circulating, underscoring the serious nature of the regulatory directive.

Further investigations by the MCAZ revealed that the recall was prompted by confirmed out-of-specification results. These quality concerns were detected during stability testing of the affected medicines, indicating that the products did not meet the required standards over time. This `MCAZ Nifedipine drug recall Zimbabwe` highlights the critical role of continuous monitoring in ensuring public safety.

The Medicines Control Authority of Zimbabwe (MCAZ), the statutory body entrusted with regulating the safety, quality, and effectiveness of medicines within the country, classified this as a Class Two recall. This classification signifies a serious health risk, necessitating a comprehensive withdrawal of the affected products from all levels of the supply chain, extending down to the retail level.

Consequently, all pharmacies and health facilities are mandated to withdraw the compromised stock immediately. Crucially, the directive also extends to patients who may already possess these specific batches, requiring their notification and the return of the medication. This broad scope underscores the urgency and potential public health impact of the `Class Two drug recall Zimbabwe`.

Beyond Nifedipine, the same round of stability testing also identified quality issues with Levodopa/Carbidopa tablets, also produced by Remedica. These tablets are vital for the treatment of Parkinson's disease and Parkinsonism, making the `Zimbabwe Levodopa Carbidopa recall` equally significant for patient care.

The recall of Nifedipine and Levodopa/Carbidopa tablets carries substantial implications for public health in Zimbabwe, given their widespread use for critical conditions such as hypertension, heart ailments, and Parkinson's disease. The `Remedica Nifedipine recall` and the associated Levodopa/Carbidopa issues underscore the indispensable nature of stringent post-market surveillance conducted by regulatory bodies like the `Medicines Control Authority of Zimbabwe`.

For pharmaceutical companies, distributors, and healthcare providers operating in Zimbabwe, this event serves as a stark reminder of the paramount importance of `pharmaceutical compliance Zimbabwe`. Compliance officers must ensure the immediate and complete withdrawal of the specified Nifedipine batches and Levodopa/Carbidopa tablets from all supply chain levels, including robust patient notification procedures. Failure to adhere to these directives could lead to significant regulatory penalties and product liability risks.

This incident highlights the critical need for robust post-market surveillance and recall protocols within the pharmaceutical industry to safeguard patient well-being and maintain public trust in medicinal products. The proactive measures taken by MCAZ are essential in upholding the integrity of the country's drug supply.

Compliance officers in pharmaceutical companies, distributors, and healthcare providers in Zimbabwe must ensure immediate and complete withdrawal of the specified Nifedipine batches (112033, 117367) and Levodopa/Carbidopa tablets from all supply chain levels, including patient notification, to mitigate regulatory penalties and product liability risks under MCAZ directives. This highlights the critical need for robust post-market surveillance and recall protocols.

Source: Original reporting via Ministry of Health statement